Teragen Bio (CEO Baek Sun-myeong) signed a memorandum of understanding with SML Biopharm (CEO Nam Jae-hwan) on the 19th to develop cancer vaccines using neoantigens.
Through this agreement, the two companies plan to pursue R&D collaboration, research to commercialize next-generation vaccine platforms and expand pipelines, and mutual sharing of technology.
In particular, Teragen Bio will use SML Biopharm’s LNP (lipid nanoparticle) drug delivery technology to verify the delivery efficiency of neoantigen-based mRNA and intends to accelerate the development of patient-tailored cancer therapeutic vaccines through clinical development.
SML Biopharm is developing various vaccines and therapeutics using its in-house developed mRNA expression constructs and LNP delivery platform technology.
Cancer patients have unique somatic gene mutations, and about 0.1–2% of these may become neoantigens capable of inducing an immune response. However, the immune systems of cancer patients often fail to properly recognize these neoantigens, weakening the immune response. Accordingly, the approach of externally administering neoantigen vaccines to activate anti-cancer immune responses is attracting attention. CEO Baek Sun-myeong explained, “Teragen Bio aims to maximize patient immune responses through innovative patient-tailored neoantigen-targeted cancer vaccine design and the underlying technologies that efficiently deliver them to immune cells, with the goal of global drug development.”
He added, “This collaboration is meaningful because it allows us to secure an efficient delivery vehicle capable of delivering neoantigens. Going forward, we will combine the strengths of both companies to pursue joint cancer vaccine development.”
CEO Nam Jae-hwan said, “This collaboration will be a significant stepping stone for both Teragen Bio and SML Biopharm. Based on the expertise of both companies, we expect to accelerate the development of cancer therapeutic vaccines.”
Medical Today https://mdtoday.co.kr/news/view/1065599396456239 Newsis https://www.newsis.com/view/NISX20241219_0003004001 Yakup News https://www.yakup.com/news/index.html?mode=view&cat=12&nid=304116 Rapportian https://www.rapportian.com/news/articleView.html?idxno=215558
